eligibility_summary
Include: adults 18–70 with r/r AML, recovered from prior tx, ECOG ≤2, survival ≥3 mo, adequate organ function (liver/renal/Hgb/SpO2/LVEF), neg pregnancy test, contraception during Tx + 2 y. Exclude: APL, CNS disease, active infxn (HBV/HCV/HIV/syphilis, CMV >500), severe allergy, cardiac dz ≤12 mo, transplant, immunosuppression, auto‑SCT <3 mo, neuro autoimmune/cerebrovascular, oncologic emergency, live vaccine <4 wk, psychiatric illness/substance abuse, major surgery <4 wk, or PI judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2, single-arm trial in relapsed/refractory AML testing anti‑TIM‑3/CD123 CAR‑T cells (autologous, gene‑modified cellular immunotherapy). Intervention: dual‑target chimeric antigen receptor T cells engineered to bind TIM‑3 (T cell immunoglobulin and mucin domain‑3) and CD123 (IL‑3 receptor α). Mechanism: CAR engagement activates T‑cell killing to eliminate leukemia stem cells (LSCs) and AML blasts, aiming for higher specificity by exploiting TIM‑3’s absence on normal HSC/progenitors. Cells/pathways targeted: TIM‑3+ CD123+ LSCs, CD123+ AML cells. Goal: maintain anti‑LSC activity while reducing on‑target/off‑tumor toxicity to CD123+ normal myeloid/HSC cells seen with CD123‑only CAR‑T.